688443 智翔金泰
已收盘 02-09 15:00:01
资讯
新帖
简况
智翔金泰连亏5年 2023年上市募资34.7亿元
中金财经 · 02-02
智翔金泰连亏5年 2023年上市募资34.7亿元
智翔金泰（688443）披露2025年年度业绩预告，1月29日股价下跌3.22%
证券之星 · 01-29
智翔金泰（688443）披露2025年年度业绩预告，1月29日股价下跌3.22%
智翔金泰(688443.SH)发预亏，预计2025年年度归母净亏损4.81亿元至5.87亿元
智通财经 · 01-29
智翔金泰(688443.SH)发预亏，预计2025年年度归母净亏损4.81亿元至5.87亿元
【机构调研记录】德邦基金调研智翔金泰
证券之星 · 01-27
【机构调研记录】德邦基金调研智翔金泰
股市必读：智翔金泰（688443）1月26日披露最新机构调研信息
证券之星 · 01-27
股市必读：智翔金泰（688443）1月26日披露最新机构调研信息
智翔金泰：1月19日组织现场参观活动，华安证券、广州知本复利等多家机构参与
证券之星 · 01-26
智翔金泰：1月19日组织现场参观活动，华安证券、广州知本复利等多家机构参与
智翔金泰跌1.74% 连亏4年3季2023年上市募34.7亿元
中金财经 · 01-22
智翔金泰跌1.74% 连亏4年3季2023年上市募34.7亿元
智翔金泰跌2.12% 连亏4年3季2023年上市募34.7亿元
中金财经 · 01-19
智翔金泰跌2.12% 连亏4年3季2023年上市募34.7亿元
每周股票复盘：智翔金泰（688443）独立董事胡耘通因工作原因离任
证券之星 · 01-18
每周股票复盘：智翔金泰（688443）独立董事胡耘通因工作原因离任
智翔金泰（688443）披露独立董事离任公告，1月16日股价上涨0.96%
证券之星 · 01-16
智翔金泰（688443）披露独立董事离任公告，1月16日股价上涨0.96%
智翔金泰跌1.51% 连亏4年3季2023年上市募34.7亿
中金财经 · 01-12
智翔金泰跌1.51% 连亏4年3季2023年上市募34.7亿
每周股票复盘：智翔金泰（688443）GR1803注射液纳入优先审评
证券之星 · 01-11
每周股票复盘：智翔金泰（688443）GR1803注射液纳入优先审评
智翔金泰：GR1803注射液被纳入优先审评品种名单
证券之星 · 01-09
智翔金泰：GR1803注射液被纳入优先审评品种名单
1月9日智翔金泰涨11.17%，方正富邦鑫诚12个月持有混合A基金重仓该股
中金财经 · 01-09
1月9日智翔金泰涨11.17%，方正富邦鑫诚12个月持有混合A基金重仓该股
ORR高达89.5%！智翔金泰BCMA/CD3双抗申报上市
医药魔方 · 01-08
ORR高达89.5%！智翔金泰BCMA/CD3双抗申报上市
智翔金泰(688443.SH)：GR1803注射液附条件上市申请获得受理
智通财经 · 01-08
智翔金泰(688443.SH)：GR1803注射液附条件上市申请获得受理
每周股票复盘：智翔金泰（688443）变更2025年度签字注册会计师
证券之星 · 2025-12-28
每周股票复盘：智翔金泰（688443）变更2025年度签字注册会计师
智翔金泰跌1% 连亏4年3季2023年上市募34.7亿
中金财经 · 2025-12-08
智翔金泰跌1% 连亏4年3季2023年上市募34.7亿
智翔金泰(688443.SH)：赛立奇单抗注射液纳入2025年国家医保目录
智通财经 · 2025-12-07
智翔金泰(688443.SH)：赛立奇单抗注射液纳入2025年国家医保目录
每周股票复盘：智翔金泰（688443）取消监事会并召开业绩说明会
证券之星 · 2025-11-23
每周股票复盘：智翔金泰（688443）取消监事会并召开业绩说明会
加载更多
公司概况
公司名称：
重庆智翔金泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-06-20
主营业务：
重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产与销售。公司的主要产品是抗体药物。
发行价格：
37.88
{"stockData":{"symbol":"688443","market":"SH","secType":"STK","nameCN":"智翔金泰","latestPrice":29.01,"timestamp":1770620401000,"preClose":28.35,"halted":0,"volume":4031263,"delay":0,"changeRate":0.0233,"floatShares":117000000,"shares":367000000,"eps":-1.5914,"marketStatus":"已收盘","change":0.66,"latestTime":"02-09 15:00:01","open":28.35,"high":29.85,"low":28.2,"amount":118000000,"amplitude":0.0582,"askPrice":29.01,"askSize":72,"bidPrice":29,"bidSize":361,"shortable":0,"etf":0,"ttmEps":-1.5914,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770687000000},"marketStatusCode":5,"adr":0,"adjPreClose":28.35,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":31.19,"lowLimit":25.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":366680000,"isCdr":false,"pbRate":5.95,"roa":"--","roe":"--","epsLYR":-2.17,"committee":0.243323,"marketValue":10637000000,"turnoverRate":0.0345,"status":0,"afterMarket":{"amount":0,"volume":0,"close":29.01,"buyVolume":0,"sellVolume":0,"time":1770622437558,"indexStatus":"已收盘 02-09 15:30:00","preClose":28.35},"floatMarketCap":3385000000},"requestUrl":"/m/hq/s/688443","defaultTab":"news","newsList":[{"id":"2608836137","title":"智翔金泰连亏5年 2023年上市募资34.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608836137","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608836137?lang=zh_cn&edition=full","pubTime":"2026-02-02 10:54","pubTimestamp":1770000849,"startTime":"0","endTime":"0","summary":"中国经济网北京2月2日讯 智翔金泰 日前披露2025年年度业绩预告。经财务部门初步测算，公司预计2025年年度实现营业收入20,944.98万元到25,087.94万元，与上年同期相比增加17,935.48万元到22,078.44万元，同比增长595.96%到733.62%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元(不含税)，其中，保荐承销费16,495.98万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260202/31991670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2607035425","title":"智翔金泰（688443）披露2025年年度业绩预告，1月29日股价下跌3.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607035425","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607035425?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:30","pubTimestamp":1769697038,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，智翔金泰报收于28.55元，较前一交易日下跌3.22%，最新总市值为104.69亿元。该股当日开盘29.5元，最高29.53元，最低28.3元，成交额达1.56亿元，换手率为4.65%。近日，公司披露《2025年年度业绩预告》。业绩变动主要因首款产品金立希销售收入增长及确认GR1803注射液授权许可收入，同时2025年无股份支付费用。本次业绩预告未经注册会计师审计。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2607082444","title":"智翔金泰(688443.SH)发预亏，预计2025年年度归母净亏损4.81亿元至5.87亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607082444","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607082444?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:47","pubTimestamp":1769690837,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰 发布2025年年度业绩预告，预计2025年年度归属于母公司所有者的净利润为-48,063.73万元到-58,744.56万元，与上年同期相比，亏损减少20,982.80万元到31,663.63万元，同比减少26.32%到39.71%。报告期内，公司坚持源头创新，高效推进各在研项目进度。同时，公司2022年针对核心团队实施的股权激励计划服务期已于2024年届满，2025年度无股份支付费用，因此报告期内的相应费用减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"智翔金泰(688443.SH)发预亏，预计2025年年度归母净亏损4.81亿元至5.87亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2606227670","title":"【机构调研记录】德邦基金调研智翔金泰","url":"https://stock-news.laohu8.com/highlight/detail?id=2606227670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606227670?lang=zh_cn&edition=full","pubTime":"2026-01-27 08:13","pubTimestamp":1769472829,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月26日披露的机构调研信息，德邦基金近期对1家上市公司进行了调研，相关名单如下：1）智翔金泰 调研纪要：赛立奇单抗的两个适应症已于2025年12月成功纳入国家医保目录，并自2026年1月1日起正式执行。德邦基金成立于2012年，截至目前，资产管理规模696.73亿元，排名80/212；资产管理规模543.12亿元，排名75/212；管理公募基金数72只，排名84/212；旗下公募基金经理16人，排名85/212。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700007156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2606247473","title":"股市必读：智翔金泰（688443）1月26日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2606247473","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606247473?lang=zh_cn&edition=full","pubTime":"2026-01-27 01:27","pubTimestamp":1769448431,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，智翔金泰报收于29.25元，上涨0.03%，换手率4.92%，成交量5.74万手，成交额1.65亿元。来自机构调研要点：GR1802注射液特应性皮炎适应症上市申请已获受理，目前处于审评阶段。赛立奇单抗的两个适应症已于2025年12月纳入国家医保目录，并自2026年1月1日起实施，有助于提升医院准入效率和患者治疗依从性。公司于2025年7月完成股份回购796,100股，拟用于员工持股计划或股权激励，具体方案将结合经营情况制定，并按规定履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2606198432","title":"智翔金泰：1月19日组织现场参观活动，华安证券、广州知本复利等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2606198432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606198432?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:19","pubTimestamp":1769422740,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月26日智翔金泰发布公告称公司于2026年1月19日组织现场参观活动，华安证券、广州知本复利、天风医药、德邦基金、嘉实基金、东方红基金、西藏君汉胜者、上海微方私募、聚石基金、杭州领睿投资参与。赛立奇单抗的两个适应症已于2025年12月成功纳入国家医保目录，并自2026年1月1日起正式执行，体现了医保政策对国产创新药价值的认可与支持。智翔金泰主营业务：抗体药物的研发、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600024844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","BK0239","BK0183","600909","BK0201","688443"],"gpt_icon":0},{"id":"2605461475","title":"智翔金泰跌1.74% 连亏4年3季2023年上市募34.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605461475","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605461475?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:21","pubTimestamp":1769073672,"startTime":"0","endTime":"0","summary":"中国经济网北京1月22日讯 智翔金泰 今日股价下跌，截至收盘，该股报28.85元，跌幅1.74%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰已连亏4年3季。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产生的现金流量净额为-2.61亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260122/31964190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2604184564","title":"智翔金泰跌2.12% 连亏4年3季2023年上市募34.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604184564","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604184564?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:10","pubTimestamp":1768813810,"startTime":"0","endTime":"0","summary":"中国经济网北京1月19日讯 智翔金泰 今日股价下跌，截至收盘，该股报30.00元，跌幅2.12%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰已连亏4年3季。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产生的现金流量净额为-2.61亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260119/31953583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2604255999","title":"每周股票复盘：智翔金泰（688443）独立董事胡耘通因工作原因离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2604255999","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604255999?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:51","pubTimestamp":1768679467,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，智翔金泰报收于30.65元，较上周的32.44元下跌5.52%。本周，智翔金泰1月12日盘中最高价报32.82元。本周关注点公司公告汇总：独立董事胡耘通因工作原因申请离任，辞职将待股东大会选举新任后生效。公司公告汇总关于公司独立董事离任的公告重庆智翔金泰生物制药股份有限公司独立董事胡耘通因工作原因申请辞去第二届董事会独立董事、董事会薪酬与考核委员会主任委员及审计委员会委员职务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2603443961","title":"智翔金泰（688443）披露独立董事离任公告，1月16日股价上涨0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603443961","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603443961?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:34","pubTimestamp":1768556085,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，智翔金泰报收于30.65元，较前一交易日上涨0.96%，最新总市值为112.39亿元。公司近日发布公告称，重庆智翔金泰生物制药股份有限公司独立董事胡耘通因工作原因申请辞去第二届董事会独立董事、董事会薪酬与考核委员会主任委员及审计委员会委员职务。其辞职将在公司股东大会选举产生新任独立董事后生效，在此之前胡耘通将继续履行职责。胡耘通先生未持有公司股份，不存在未履行完毕的公开承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600028786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2602151255","title":"智翔金泰跌1.51% 连亏4年3季2023年上市募34.7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2602151255","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602151255?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:18","pubTimestamp":1768213083,"startTime":"0","endTime":"0","summary":"中国经济网北京1月12日讯 智翔金泰 今日收报31.95元，跌幅1.51%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰已连亏4年3季。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产生的现金流量净额为-2.61亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260112/31935008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2602398945","title":"每周股票复盘：智翔金泰（688443）GR1803注射液纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2602398945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602398945?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:30","pubTimestamp":1768077025,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，智翔金泰报收于32.44元，较上周的27.24元上涨19.09%。自愿披露关于GR1803注射液纳入优先审评品种名单的公告重庆智翔金泰生物制药股份有限公司公告，其自主研发的GR1803注射液被国家药品监督管理局药品审评中心纳入优先审评品种名单。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2602321891","title":"智翔金泰：GR1803注射液被纳入优先审评品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602321891?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:36","pubTimestamp":1767951385,"startTime":"0","endTime":"0","summary":"智翔金泰(688443.SH)公告称，公司产品GR1803注射液被国家药品监督管理局药品审评中心纳入优先审评品种名单，拟定适应症为既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患者。GR1803注射液是一款由公司自主研发的双特异性抗体药物，注册分类为治疗用生物制品1类。新药上市申请尚需经过多个环节，产品能否成功上市及上市时间存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900028822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2602233693","title":"1月9日智翔金泰涨11.17%，方正富邦鑫诚12个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602233693","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602233693?lang=zh_cn&edition=full","pubTime":"2026-01-09 15:54","pubTimestamp":1767945245,"startTime":"0","endTime":"0","summary":"证券之星消息，1月9日智翔金泰涨11.17%创60日新高，收盘报32.44元，换手率9.94%，成交量11.59万手，成交额3.64亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为方正富邦基金的方正富邦鑫诚12个月持有混合A。方正富邦鑫诚12个月持有混合A目前规模为0.24亿元，最新净值1.0641，较上一交易日上涨0.24%，近一年上涨12.05%。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/09/20260109744010.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/09/20260109744010.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260109/31929468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2601490365","title":"ORR高达89.5%！智翔金泰BCMA/CD3双抗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601490365","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601490365?lang=zh_cn&edition=full","pubTime":"2026-01-08 19:01","pubTimestamp":1767870060,"startTime":"0","endTime":"0","summary":"1月8日，智翔金泰宣布双抗药物GR1803的附条件上市申请已获得国家药监局受理，用于治疗既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患者。GR1803是智翔金泰自主研发的一款BCMA/CD3双抗药物，其结合BCMA的亲和力较结合CD3的亲和力高两个数量级。2025年11月，智翔金泰在ASH 2025年会上公布了GR1803治疗R/R MM的I期研究数据。结果显示，在至少接受了一次疗效评估的57例患者中，客观缓解率为89.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-08/doc-inhfqyhi5239845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ORR","688443","BK0239"],"gpt_icon":0},{"id":"2601357820","title":"智翔金泰(688443.SH)：GR1803注射液附条件上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601357820","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601357820?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:35","pubTimestamp":1767864935,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰(688443.SH)发布公告，近日，公司收到了国家药品监督管理局下发的关于“GR1803注射液”境内生产药品注册上市许可申请的《受理通知书》，本次申请附条件批准上市的适应症为：本品适用于既往至少接受过三线治疗(包括一种蛋白酶体抑制剂、一种免疫调节剂和一种抗CD38单克隆抗体)的复发或难治性多发性骨髓瘤成人患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智翔金泰(688443.SH)：GR1803注射液附条件上市申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2594479632","title":"每周股票复盘：智翔金泰（688443）变更2025年度签字注册会计师","url":"https://stock-news.laohu8.com/highlight/detail?id=2594479632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594479632?lang=zh_cn&edition=full","pubTime":"2025-12-28 05:03","pubTimestamp":1766869391,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，智翔金泰报收于26.91元，较上周的26.33元上涨2.2%。本周，智翔金泰12月25日盘中最高价报27.28元。公司公告汇总重庆智翔金泰生物制药股份有限公司于2025年12月24日发布公告，因原签字注册会计师徐伟东先生工作变动，不再担任公司2025年度审计项目签字会计师。本次变更为事务所内部工作调整，不影响公司年度审计工作的正常进行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0},{"id":"2589339345","title":"智翔金泰跌1% 连亏4年3季2023年上市募34.7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2589339345","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589339345?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:47","pubTimestamp":1765187224,"startTime":"0","endTime":"0","summary":"中国经济网北京12月8日讯 智翔金泰 今日收报27.67元，跌幅1.00%。 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14万元。 智翔金泰已连亏4年3季。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产生的现金流量净额为-2.61亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251208/31850936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2589987957","title":"智翔金泰(688443.SH)：赛立奇单抗注射液纳入2025年国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589987957","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589987957?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:18","pubTimestamp":1765095512,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰(688443.SH)发布公告，公司自主研发的赛立奇单抗注射液(金立希)成功纳入《国家基本医疗保险、生育保险和工伤保险药品目录》(以下简称“国家医保目录”)。新版国家医保目录将自2026年1月1日起正式实施。赛立奇单抗注射液是一款由公司自主研发的重组全人源抗IL-17A单克隆抗体，注册分类为治疗用生物制品Ⅰ类，作用靶点为IL-17A。该产品可特异性结合血清中的IL-17A蛋白，阻断IL-17A与IL-17RA的结合，抑制炎症的发生和发展，从而对IL-17A过表达的斑块状银屑病、放射学阳性中轴型脊柱关节炎等自身免疫性疾病达到治疗效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688443"],"gpt_icon":0},{"id":"2585105160","title":"每周股票复盘：智翔金泰（688443）取消监事会并召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585105160","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585105160?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:48","pubTimestamp":1763840895,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，智翔金泰报收于26.79元，较上周的29.46元下跌9.06%。重庆智翔金泰生物制药股份有限公司将于2025年11月28日15:00-16:00通过网络互动方式在价值在线平台召开2025年第三季度业绩说明会，介绍公司经营业绩、发展战略等情况。重庆智翔金泰生物制药股份有限公司于2025年11月18日召开临时股东大会，审议通过取消监事会、修订公司章程等议案，董事会设职工代表董事一名。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770641153318,"stockEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0098},{"period":"3month","weight":-0.0221},{"period":"6month","weight":-0.1277},{"period":"1year","weight":0.1427},{"period":"ytd","weight":0.0407}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智翔金泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12640人(较上一季度增加7.75%)","perCapita":"9231股","listingDate":"2023-06-20","address":"重庆市巴南区麻柳大道699号2号楼A区","registeredCapital":"36668万元","survey":" 重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产与销售。公司的主要产品是抗体药物。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智翔金泰(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智翔金泰(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智翔金泰,688443,智翔金泰股票,智翔金泰股票老虎,智翔金泰股票老虎国际,智翔金泰行情,智翔金泰股票行情,智翔金泰股价,智翔金泰股市,智翔金泰股票价格,智翔金泰股票交易,智翔金泰股票购买,智翔金泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智翔金泰(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智翔金泰(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}